What is the Return on Assets (ROA) of Savara this year?
The Return on Assets (ROA) of Savara is -0.31 undefined this year.
Savara ROA 2024
Savara ROA
-0.31
Ticker
SVRA
ISIN
US8051111016
WKN
A2DQ2B
In 2024, Savara's return on assets (ROA) was -0.31, a 12.88% increase from the -0.27 ROA in the previous year.
Savara Aktienanalyse
What does Savara do?
Savara Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas. Savara initially focused on treating cystic fibrosis, a genetic disease that can cause severe lung problems. The company developed an innovative therapy based on the use of liposomes, tiny bubbles that can deliver medication directly to the lungs. This method was considered promising and received orphan drug status from the FDA, meaning it is intended for the treatment of rare diseases. However, due to high costs associated with developing and approving a new medication for cystic fibrosis, Savara decided to redefine its goals and focus on other rare respiratory diseases. The company's business model is based on identifying promising therapy approaches for these diseases and developing them into approvable medications. Savara collaborates closely with leading experts and scientists in the field of respiratory diseases. Its main therapy areas include cystic fibrosis, pulmonary fibrosis, and rare lung diseases. Savara has a special focus on developing liposome-based therapies, which have the potential to target the affected areas in the lungs and enhance the effects of other medications. Currently, the company offers three products: - AeroVanc: A liposome-based inhaled antibiotic used to treat cystic fibrosis-induced chronic lung infections. AeroVanc is the first FDA-approved medication in Savara's history. - Molgradex: A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for the treatment of autoimmune pulmonary alveolitis (also known as extrinsic allergic alveolitis). - AVAIL: A liposome-based inhaled antibiotic currently in Phase II of clinical development, being developed to treat non-tuberculous mycobacterial (NTM) lung infections. Savara has also formed partnerships with other companies and organizations to advance its research and development. Partners include the Cystic Fibrosis Foundation, the National Institutes of Health (NIH), and the European Respiratory Society. In summary, Savara Inc is a biotechnology company focused on developing therapies for rare respiratory diseases. The company has developed a promising technology platform and collaborates closely with leading experts and scientists in the field. Savara has a range of products on the market, including the first FDA-approved medication in the company's history. Savara ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Savara's Return on Assets (ROA)
Savara's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Savara's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Savara's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Savara’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Savara stock
What was the ROA of Savara compared to the previous year?
The ROA of Savara has increased by 12.88% compared to the previous year.
What consequences do high ROA have for investors of Savara?
A high ROA is advantageous for investors of Savara, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Savara?
A low ROA can be unfavorable for investors of Savara as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Savara affect the company?
An increase in ROA of Savara can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Savara impact the company?
A reduction in the ROA of Savara can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Savara?
Some factors that can influence the ROA of Savara include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Savara important for investors?
The ROA of Savara is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Savara take to improve ROA?
To improve ROA, Savara can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Savara pay?
Over the past 12 months, Savara paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Savara is expected to pay a dividend of 0 USD.
What is the dividend yield of Savara?
The current dividend yield of Savara is .
When does Savara pay dividends?
Savara pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Savara?
Savara paid dividends every year for the past 0 years.
What is the dividend of Savara?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Savara located?
Savara is assigned to the 'Health' sector.
Wann musste ich die Aktien von Savara kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Savara from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.
When did Savara pay the last dividend?
The last dividend was paid out on 11/19/2024.
What was the dividend of Savara in the year 2023?
In the year 2023, Savara distributed 0 USD as dividends.
In which currency does Savara pay out the dividend?
The dividends of Savara are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Savara
Our stock analysis for Savara Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Savara Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
